Protons against cancer: New research beamline for innovative radiotherapies
Prof. Dr Judith Reindl and PhD student Aikaterini Rousseti (from left to right) from the University of the Bundeswehr Munich present the experimental station for biological samples which is installed at the new Minibee beamline at HZB. © Kevin Fuchs / HZB
Magnetic quadrupoles focus the proton beam in front of the experiment platform. © Kevin Fuchs / HZB
Together with the University of the Bundeswehr Munich, the HZB has set up a new beamline for preclinical research. It will enable experiments on biological samples on innovative radiation therapies with protons.
The proton accelerator at the Helmholtz-Zentrum Berlin (HZB) has been used for about 25 years to combat certain types of eye tumours. So far, over 4800 people have benefited from proton eye tumour therapy, which is carried out in collaboration with Charité – Universitätsmedizin Berlin.
Now, the proton accelerator at HZB also offers the option of conducting preclinical research: A mini-beamline for preclinical experiments (Minibee) has been set up for this purpose together with the University of the Bundeswehr in Munich. The HZB's Proton Therapy Department has built the beam guidance and control system for the minibeams. The University of the Bundeswehr in Munich, with Prof. Judith Reindl from the Institute of Applied Physics and Measurement Technology and the Section of Biomedical Radiation Physics, installed a platform for image-guided irradiation of biological samples. This will enable joint experiments on radiobiology and innovative radiation therapy in the future.
‘At Minibee, we can use medical research to investigate how changes in parameters and settings of the proton beam affect the treatment,’ says Judith Reindl. Among other things, Minibee is designed to generate ultrashort proton flashes (FLASH therapy) or needle-fine radiation (beamlets). ‘Our aim is to develop new methods that effectively destroy tumours while providing even better protection for healthy tissue,’ says Prof. Dr. Andrea Denker, head of the Department of Proton Therapy at HZB.
arö
https://www.helmholtz-berlin.de/pubbin/news_seite?nid=28606;sprache=en
- Copy link
-
AI in Chemistry: Study Highlights Strengths and Weaknesses
How well does artificial intelligence perform compared to human experts? A research team at HIPOLE Jena set out to answer this question in the field of chemistry. Using a newly developed evaluation method called “ChemBench,” the researchers compared the performance of modern language models such as GPT-4 with that of experienced chemists.
-
TH Wildau and Helmholtz Zentrum Berlin signed comprehensive cooperation
On 21 May 2025, the Technical University of Applied Sciences Wildau (TH Wildau) and the Helmholtz-Zentrum Berlin für Materialien und Energie (HZB), signed a comprehensive cooperation agreement. The aim is to further promote networking and cooperation, particularly in basic research, to increase the scientific excellence of both partners and to develop competence networks in research, teaching and the training of young scientists.
-
Green hydrogen: MXene boosts the effectiveness of catalysts
MXenes are adept at hosting catalytically active particles. This property can be exploited to create more potent catalyst materials that significantly accelerate and enhance the oxygen evolution reaction, which is one of the bottlenecks in the production of green hydrogen via electrolysis using solar or wind power. A detailed study by an international team led by HZB chemist Michelle Browne shows the potential of these new materials for future large-scale applications. The study is published in Advanced Functional Materials.